Is Thymosin Alpha-1 Legal in North Carolina? How to Access It Legally
Key numbers
- 1.6 mgZadaxin label dose per injection in Italy, the only authorized-country dosing given (no US-approved dose exists)Source: fda.gov, as cited Nov 7, 2026
- 17 noFDA advisory committee vote against adding thymosin alpha-1 to the pharmacy bulks listSource: fda.gov, as cited Nov 7, 2026
- RR 0.53Possible lower all-cause mortality with thymosin alpha-1 in adults with chronic hepatitis B (very low certainty)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- FDA approval / none; FDA found no US application [1]
- Approved elsewhere / Italy, India and Hong Kong [1]
- FDA list, state-licensed pharmacies / in none of the three categories [2]
- FDA list, outsourcing facilities / category 3, nominated without adequate support [3]
- FDA advisory committee vote / 17 no, 4 yes, December 2024 [5]
- US-approved dose / none [1]
What is thymosin alpha-1?
A 28-amino-acid peptide originally isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version with the same sequence [1]. Zadaxin is the brand of the finished 1.6 mg injection sold outside the United States and is not interchangeable with bulk thymosin alpha-1 powder [1].
Is it FDA-approved or compoundable?
FDA found no US application for thymosin alpha-1 [1]. It is authorized in Italy as an adjuvant to influenza vaccination in immunocompromised people, in India for chronic hepatitis B in adults 18 or older, and in Hong Kong [1].
It appears in none of the three categories on FDA's list for state-licensed pharmacies (updated May 14, 2026), and FDA's category 1 policy does not apply to it [2]. On FDA's list for outsourcing facilities it is category 3, 'nominated without adequate support' [3]. On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no against adding it to the pharmacy bulks list [5]. FDA's page on bulk substances that may raise significant safety risks now lists thymosin alpha-1 only in the 'nominated but withdrawn' table, because it came off category 2 when the nominators withdrew; FDA's posted concern about a significant risk of immunogenicity for certain routes of administration remains [6]. The October 2026 HHS draft enforcement-discretion policy does not name thymosin alpha-1 among its six peptides [4].
What about North Carolina?
North Carolina's pharmacy and medical board rules are not covered here. Federally, no thymosin alpha-1 product is approved, and we found no FDA or HHS action allowing its compounding [1][4].
Questions worth asking
What is known about dosing and safety?
No US-approved dose exists [1]. Italy's Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks from the first vaccination, repeated from week 8 to week 12; the label says not for children, is contraindicated in pregnancy and breastfeeding, and advises caution in people with allergies or autoimmune disease [1].
FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1 [1]. A 2026 Cochrane review of 10 randomized trials in 1,349 adults with chronic hepatitis B found possible lower all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people; very low certainty) and possibly fewer serious adverse events than the comparison treatments (RR 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low certainty); the reviewers said they are 'not sure' Ta1 helps [7].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 legal in North Carolina?
Can a pharmacy compound thymosin alpha-1?
Is thymosin alpha-1 approved in any country?
Does WADA prohibit thymosin alpha-1?
References
Show all 8 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
- World Anti-Doping Agency.